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Previewspool to be determined. To answer this
question would require an inducible sys-
tem in which Rag1-Cre expression can
be temporally controlled.
Just like the adult lymphoid-primed
multipotent progenitor (LMPP) identified
by the same group a few years ago
(Adolfsson et al., 2005), this LinKit+Flt3+
IL7Ra+ embryonic immune-restricted
progenitorhasGM,B,andTcell potentials,
but nomegakaryocyte-erythroid (MkE) po-
tential. These findings suggest that one of
the earliest hematopoietic lineage deci-
sions is a restriction process of the lym-
pho-myeloid lineage and a segregation of
this potential from the MkE lineage. Why
this lineage separation occurs at this early
stage is currently unclear, but may be ex-
plained by an earlier requirement for large
numbers of erythroid cells, which are pro-
vided first by the primitive wave and then
by the well-characterized erythro-myeloid
progenitor of the second wave, which
does not seem to possess lymphoid
potential and already arises at E8.25
(reviewed in Frame et al., 2013). Whether
these two important early progenitors,
the erythro-myeloid progenitor and the
immune-restricted progenitor, share a
commonorigin andmight even havediffer-
entiated from the same precursors re-
mains to be explored.510 Cell Stem Cell 13, November 7, 2013 ª2The immune-restricted progenitor iden-
tified in this study may also prove relevant
to the study of pediatric leukemias, some
of which are known to initiate in utero.
While most patients present with acute
lymphoblastic leukemia, some are diag-
nosed with poor prognosis biphenotypic
leukemia, suggesting that the cell of origin
possessed both lymphoid and myeloid
potentials. Since the myeloid potential
of the immune-restricted progenitor
identified by Bo¨iers et al. was shown to
decrease over the course of develop-
ment, it may also provide crucial clues
as to the timing of preleukemic transloca-
tions. For this cell to become a useful
therapeutic target, however, would
require further studies into its in vivo
function. Nevertheless, Bo¨iers et al.’s
identification of an LMPP-like cell present
in the mammalian embryo as early as
E9.5, prior to the emergence of HSCs,
represents an important study as it
sheds light on the development of
both the myeloid innate and lymphoid
adaptive immune system and describes
the myeloid-lymphoid versus MkE res-
triction as one of the earliest hematopoi-
etic lineage decisions. It also highlights
the role of the yolk sac in setting up the
first hematopoietic/immune system dur-
ing development.013 Elsevier Inc.REFERENCES
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Recently in Cell, Wapinski et al. (2013) investigated the epigenetic mechanisms underlying the direct conver-
sion of fibroblasts to induced neurons (iNs). They found that Ascl1 acts as a pioneer factor at neurogenic loci
marked by a closed ‘‘trivalent’’ chromatin state in cells permissive to direct conversion, but not in restrictive
cell types.Lineage-specific transcription factors
define cell fate during development. Intu-
itively, ectopic overexpression of these
transcription factors can redirect cell
fate. One of the most dramatic examples
of engineered cell fate change is the deri-
vation of induced pluripotent stem cells(iPSCs) by four transcription factors
(classically Oct4, Sox2, Klf4, and c-Myc)
that reprogram fully differentiated cells
to a pluripotent state (Takahashi and
Yamanaka, 2006). This successful cel-
lular conversion to pluripotency has also
encouraged efforts to directly reprogramone cell type to another. Although exam-
ples of direct reprogramming, or transdif-
ferentiation, already existed prior to the
advent of iPSC technology (Graf, 2011),
they have primarily involved switching
between related cells in a lineage within
















Figure 1. Pioneer Transcription Factor Ascl1 Is Recruited to Trivalent Chromatin with
H3K9me3, H3K27ac, and H3K4me1 Histone Marks
Brn2 and other transcription factors are recruited to further promote transcriptional activation for neuronal
conversion.
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Previewsconversion of murine embryonic fibro-
blasts to myoblasts through overexpres-
sion of MyoD (Davis et al., 1987), or
mature murine B cells to macrophages
through overexpression of C/EBPs (Xie
et al., 2004). In 2010, the direct reprog-
ramming field reached an important mile-
stone when Vierbuchen et al. (2010)
found that three transcription factors
(Ascl1, Brn2, and Myt1l) are sufficient to
convert mesodermal murine fibroblasts
to ectodermal neurons. Since this report,
several groups have successfully con-
verted somatic cells from various tissue
sources into a variety of neuronal sub-
types (Yang et al., 2011). In a recent
issue of Cell, Wapinski et al. (2013) begin
to address the mechanism whereby
Ascl1, Brn2, and Myt1l confer neuronal
identity to murine fibroblasts. They report
that Ascl1 is a pioneer transcription
factor occupying closed chromatin
regions containing H3K4me1, H3K27ac,
and H3K9me3, which subsequently
recruits the other factors to activate
neural pathways.
Of the three neurogenic factors, Ascl1
was already known to be essential for
inducing neuronal fate because its
overexpression alone can induce smallneuronal features in fibroblasts (Vier-
buchen et al., 2010). Wapinski et al.
(2013) demonstrate that Ascl1 acts as
a transcription activator that is respon-
sible for most of the global transcrip-
tional and genome-wide occupancy
changes during iN conversion. ChIP-
Seq analyses of Ascl1 binding revealed
that Ascl1 occupies its targets in MEFs
regardless of whether Ascl1 is ex-
pressed alone or with all three factors
(Figure 1). In addition, Ascl1 seems to
occupy its physiological targets in
MEFs, since Ascl1 binding patterns are
similar in MEFs and neural progenitor
cells (NPCs). Strikingly, Brn2 is misdir-
ected to its binding targets in the
absence of Ascl1, but properly recruited
in its presence, providing further support
for the primary role of Ascl1 in targeting
loci for activation during the induced
neuron (iN) fate switch.
To determine how Ascl1 can indepen-
dently target neurogenic loci during
reprogramming, Wapinski et al. (2013)
employed formaldehyde-assisted isola-
tion of regulatory elements followed by
massive parallel sequencing (FAIRE-
seq) technology that maps genome-
wide nucleosome location. Unexpect-Cell Stem Cell 13,edly, the authors found that Ascl1 binds
more commonly to closed chromatin,
while Brn2 and Myt1l occupy regions
with active histone marks. These data
suggest that Ascl1 acts as a pioneer fac-
tor (Zaret and Carroll, 2011) that primes
fibroblast chromatin for recruitment of
other transcription factors in addition to
activating iN related genes.
The most exciting finding of this study
involves the revelation of a trivalent chro-
matin state in genomic regions of MEFs
that are normally occupied by Ascl1 in
NPCs. While investigating whether any
epigenetic marks were responsible for
initially guiding Ascl1 to its intended
targets, Wapinski et al. noticed an
increased co-occurrence of H3K4me1,
H3K27ac, and H3K9me3 histone marks
in Ascl1 sites. These trivalent sites are
only present in cells permissive to iN re-
programming, such as MEFs, human
dermal fibroblasts, and human skeletal
muscle myoblasts, but they are not pre-
sent in restrictive cells such as human
keratinocytes and human osteoblasts.
Additionally, some Ascl1 targets not
bound in MEFs but occupied in NPCs
show less prevalence of the trivalent
state. In support of the functional role of
the trivalent mark, the authors showed
that erasure of the H3K9me3 mark by
histone demethylase JmjD2 reduced re-
programming efficiency of MEFs to iNs,
further strengthening the link between
Ascl1 accessibility in the presence of tri-
valency and iN reprogramming success.
Finally, in order to further explore the
functional role of Ascl1 during fibroblast
to neuron transdifferentiation, Wapinski
et al. tested the Ascl1 downstream target
Zfp238 for its ability to functionally replace
Ascl1 during iN conversion. Unlike Ascl1,
Zfp238 was unable to initiate repro-
gramming alone, but required at least
the addition of Myt1l. Even though the
interaction between Ascl1 and Zfp238
was not fully examined in detail, taken as
a whole, these data support a central
role of the Ascl1 pathway in the neuronal
fate switch.
There remain, however, many inter-
esting questions to be addressed in future
studies. Ascl1 is sufficient to initiate the
reprogramming process. However, when
Ascl1 is expressed alone, only occasional
Tuj1+ neuronal cells emerge. This obser-
vation points to the very strong supportive
roles for Brn2 and Myt1l or Zic1, mostNovember 7, 2013 ª2013 Elsevier Inc. 511
Cell Stem Cell
Previewslikely in the later stages of iN reprogram-
ming. In this study, Myt1l marked a
minimal number of binding sites despite
much optimization effort in ChIP, while
its addition to the reprogramming cocktail
significantly increased reprogramming
efficiency and formation of mature neu-
rons. The low iN conversion rate (2%–
8% depending on cell type) may obscure
some interactions among Ascl1 and the
supportive transcription factors. Further-
more, it will be interesting to determine
how global transcription and epigenetic
changes occur in instances when Ascl1
is excluded from the reprogramming
cocktail.
Another stimulating question from
this study is the existence of trivalent
chromatin states or similar unknown chro-
matin states that enable accessibility to
pioneer factors in other transdifferen-
tiation contexts i.e., fibroblasts to hepa-
tocytes and cardiomyocytes, or other
known and yet undiscovered conversions512 Cell Stem Cell 13, November 7, 2013 ª2(Ladewig et al., 2013). Addressing the
binding particulars of how Ascl1 re-
cognizes the trivalent state could be
used to predict a more widespread
modus operandi of ‘‘on target’’ factors.
Taken as a whole, this study’s accom-
plishments are 2-fold. First, by delving
into the mechanism of iN reprogramming,
this study has provided more support for
the soundness of using the direct conver-
sion method, because binding patterns of
essential transcription factors resemble
those found naturally, i.e., NPCs. Second,
a trivalent chromatin state is uncovered
that further underscores the importance
of a more complex combinatorial histone
code, just like the discovery of bivalent
promoters in embryonic stem cells did
previously (Bernstein et al., 2006).REFERENCES
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Gastrointestinal toxicity of chemoradiotherapy treatment in late-stage cancer patients limits tolerable doses
and effectiveness of treatments. Zhou and colleagues in Nature (Zhou et al., 2013) suggest that activating
Robo/Slit signaling in concert with R-Spondin potentiates Wnt signaling in intestinal stem cells and drives
successful intestinal regeneration and recovery.Over the past 5 years, there has been a
dramatic increase in our understanding
of intestinal biology, including intestinal
stem cells (ISCs), homeostasis, and
transformation (reviewed in Barker
et al., 2012). Culturing intestinal epithe-
lium as organoids in vitro is now com-
mon practice for both the small intestine
and colon (reviewed in Barker et al.,
2012). This wealth of information sug-
gests that there will be an opportunityto translate this knowledge into thera-
peutic strategies for regenerative medi-
cine. One key area where our increased
understanding should yield important
insights is intestinal injury following che-
moradiotherapy. Over recent years it has
been shown that Wnt signaling is acti-
vated during intestinal regeneration
(Ashton et al., 2010) and that R-Spondin,
a Wnt agonist, can increase proliferation
of the intestine and improve recoveryafter chemoradiotherapy (Kim et al.,
2005). Despite this, R-Spondin alone
does not appear sufficiently potent to
work as a single agent to provide an
improved clinical outcome.
To address this, Zhou and colleagues
investigated pathways that may be
active within ISCs that could potentiate
R-Spondin action and discovered the
Slit/Robo pathway as a potential collabo-
rator (Figure 1). They first used fluorescent
